Table 3.
Hospital discharge status at day 28
|
Namilumab vs usual care |
Infliximab vs usual care |
|||||
|---|---|---|---|---|---|---|
| Usual care group | Namilumab group | Difference in proportions (95% CI) | Usual care group | Infliximab group | Difference in proportions (95% CI) | |
| Overall | ||||||
| Participants | 54 | 55 | .. | 34 | 29 | .. |
| Discharged | 33 (61%) | 43 (78%) | −0·17 (−0·34 to −0·00) | 22 (65%) | 22 (76%) | −0·11 (−0·34 to 0·11) |
| In hospital | 11 (20%) | 6 (11%) | 0·09 (−0·04 to 0·23) | 7 (21%) | 3 (10%) | 0·10 (−0·07 to 0·28) |
| Death | 10 (19%) | 6 (11%) | 0·08 (−0·06 to 0·21) | 5 (15%) | 4 (14%) | 0·01 (−0·16 to 0·18) |
| Ward | ||||||
| Participants | 33 | 33 | .. | 22 | 20 | .. |
| Discharged | 28 (85%) | 29 (88%) | −0·03 (−0·20 to 0·14) | 19 (86%) | 16 (80%) | 0·06 (−0·16 to 0·29) |
| In hospital | 4 (12%) | 2 (6%) | 0·06 (−0·08 to 0·20) | 2 (9%) | 1 (5%) | 0·04 (−0·11 to 0·19) |
| Death | 1 (3%) | 2 (6%) | −0·03 (−0·13 to 0·07) | 1 (5%) | 3 (15%) | −0·10 (−0·28 to 0·07) |
| ICU | ||||||
| Participants | 21 | 22 | .. | 12 | 9 | .. |
| Discharged | 5 (24%) | 14 (64%) | −0·40 (−0·67 to −0·13) | 3 (25%) | 6 (67%) | −0·42 (−0·81 to −0·02) |
| In hospital | 7 (33%) | 4 (18%) | 0·15 (−0·11 to 0·41) | 5 (42%) | 2 (22%) | 0·19 (−0·19 to 0·58) |
| Death | 9 (43%) | 4 (18%) | 0·25 (−0·02 to 0·51) | 4 (33%) | 1 (11%) | 0·22 (−0·11 to 0·56) |
Data are n (%) unless otherwise stated. Data were available on all patients (in the modified intention-to-treat population). ICU=intensive care unit.